TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06824168: A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complet

Sponsor: Daiichi Sankyo · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06824168 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06824168 Rescue Dossier →